<DOC>
	<DOCNO>NCT01269866</DOCNO>
	<brief_summary>The purpose study determine whether Duloxetine ( cymbalta ) reduce pain severity patient Systemic Lupus Erythematosus .</brief_summary>
	<brief_title>Study Duloxetine Reduction Pain Patient With Systemic Lupus Erythematosus</brief_title>
	<detailed_description>Duloxetine ( Cymbalta ) reuptake inhibitor serotonin norepinephrine . By increase level serotonin norepinephrine , descend inhibitory pain pathway may function good . These pathway lessen perception pain . Results double blind , placebo control , clinical trial investigate effectiveness Duloxetine ( Cymbalta ) show dose 60 mg day 60 mg twice day , Duloxetine ( Cymbalta ) demonstrate significantly high rate treatment response pain compare placebo . Given positive finding clinical trial study Duloxetine ( Cymbalta ) Diabetic Peripheral Neuropathy ( Raskin et al. , 2005 ) Fibromyalgia ( e.g . Arnold et al. , 2005 ) , investigator hypothesize Duloxetine ( Cymbalta ) may reduce pain severity , frequency intensity exacerbation patient SLE .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>1 . A diagnosis Systemic Lupus Erythematosus ( SLE ) accord American College Rheumatology ( ACR ) classification criterion , visit 1 . 2 . Able swallow require medication without open crush . 3 . Male female outpatient 1865 year old visit 1 . 4 . Painful physical symptom frequency &gt; equal 2 time per week . 5 . Painful physical symptom score &gt; equal 4 BPI SF average pain question visit 1 2 . 6 . Clinical Global Impression Severity ( CGIS ) score 3 high visit 1 . 7 . Able speak , read provide informed consent . 8 . Judged investigator reliable agree keep appointment . 1 . Subjects participate investigational drug trial 30 day prior screen visit . 2 . Pregnancy , nursing . Women childbearing potential ( surgically sterilize menarche 1 year postmenopausal ) use medically accept mean contraception ( For example , oral contraceptive , contraceptive patch , implant , DepoProvera® , Norplant® , reliable barrier method/devices [ diaphragms contraceptive jelly ; cervical cap contraceptive jelly ; condom contraceptive foam ; intrauterine device ] 3 . Positive urine drug screen substance abuse . Note : If subject positive drug screen substance Visit 1 , retest may perform prior Visit 2 , judgment investigator , acceptable explanation positive result . A retest require positive result benzodiazepine hypnotic investigator confirms use within protocol criterion . 4 . Serious medical illness , include cardiovascular , hepatic , renal respiratory hematologic , endocrinologic neurologic disease , significant laboratory abnormality judge investigator . 5 . Substance/alcohol abuse dependency last 6 month . 6 . History serious suicide attempt subject judge clinically serious suicidal risk opinion investigator . 7 . Uncontrolled narrow angle glaucoma . 8 . Known hypersensitivity Duloxetine active ingredient . 9 . Treatment MAOI within 14 day prior Visit 2 potential need use MAOI study within 5 day discontinuation study drug . ( See Concomitant Medication List ) 10 . Have epilepsy history seizure disorder . 11 . Use prohibit medication include thioridazine ( Mellaril ) , potent CYP1A2 inhibitor , use drug exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Lupus Pain</keyword>
	<keyword>Lupus</keyword>
	<keyword>Pain</keyword>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>Duloxetine</keyword>
	<keyword>Cymbalta</keyword>
</DOC>